Table 2.
Summary of studies evaluating primary sclerosing cholangitis as a risk factor for colorectal neoplasia in chronic ulcerative colitis
| Ref. | UC case group (No) | Centre | End point (No) | Matched controls | Colectomy rate | Is PSC a risk factor? |
| Broomé et al[45] | Dys (17) | Hudding, Sweden | PSC (5) | Yes | 0% | Yes |
| D’Haens et al[46] | Dys (29) | Chicago, United States | Cholestasis/PSC (10) | Yes | 0% | Yes |
| Broomé et al[47] | PSC (40) | Hudding, Sweden | CRC/Dys (15) | Yes | 30% | Yes |
| Brentnall et al[48] | PSC (20) | Seattle, United States | Dys (9) | No | 0% | Yes |
| Leidenius et al[49] | PSC (45) | Helsinki, Finland | CRC/Dys (13) | Yes | 29% | Yes |
| Marchesa et al[50] | PSC (27) | Clevelan, United States | CRC (4)/Dys (14) | Yes | All postop | Yes |
| Shetty et al[51] | PSC (132) | Clevelan, United States | CRC (17)/Dys (16) | No | 0% | Yes |
| Loftus et al[52] | PSC (143) | Mayo Clinic, United States | CRC (8) | No | 37% | No |
| Nuako et al[53] | CRC (171) | Mayo Clinic, United States | PSC (30) | Yes | 14% | No |
CRC: Colorectal cancer; CRN: Colorectal neoplasia; Dys: Dysplasia; PSC: Primary sclerosing cholangitis.